Caris Life Sciences Inc. (CAI) is a Medical Specialities company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for CAI, including 2 press releases and news items, 2 earnings updates and 2 SEC filings. The most recent was published Nov 5, 2026.
CAI rankings
Financial highlights
Full financials- Revenue, TTM
- $1.05B
- Revenue growth
- +61.5%
- Net income, TTM
- $96.06M
- Net margin
- 9.2%
- Free cash flow, TTM
- $28.91M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks48+67%
2026-05-172026-11-08
Mix1590d
- Other5(33%)
- SEC Filings4(27%)
- Insider2(13%)
- Earnings2(13%)
- Analyst1(7%)
- 13D/G1(7%)
Activity · 52 weeks11878 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)
- SECSEC Form 10-Q filed by Caris Life Sciences Inc.10-Q - Caris Life Sciences, Inc. (0002019410) (Filer)
- SECCaris Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
- PRCaris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue GuidanceRevenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology testsRaises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29%IRVING, Texas, Nov. 4, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (NASDAQ:CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial HighlightsReported total revenue of $275.4 million, an increase of 27% over the
- PRCaris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer DetectionNew campaign connects AI-powered performance insights linking advanced molecular intelligence to help detect cancer in earlier stagesIRVING, Texas, Oct. 19, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading TechBio company, today announced the launch of the second commercial in a series promoting Caris Detect™, Caris' multi-cancer early detection (MCED) test, featuring three-time major champion professional golfer, Jordan Spieth. The campaign emphasizes that while modern technology can measure nearly every aspect of athletic performance, the same level of intelligence can be applied to helping people find early
- PRCaris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026IRVING, Texas, Oct. 15, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading TechBio company, today announced it will report third quarter 2026 financial results on Wednesday, November 4, 2026.Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Wednesday, November 4, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/nri9afkyA replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.About Caris Life SciencesCaris Life Sciences® (Caris) is a leading T
- PRCaris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026Eight posters will feature AI-driven approaches to treatment prediction, risk stratification and biomarker discovery advancing precision medicine across multiple cancer typesIRVING, Texas, Oct. 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present eight posters at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The research showcases the expanding impact of artificial intelligence, molecular profiling and multimodal data integration in advancing precision oncology across multiple tu
- INSIDEROfficer Denton John Russel sold $238,626 worth of shares (7,500 units at $31.82), decreasing direct ownership by 4% to 174,855 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDEROfficer Brille Brian J exercised 400,000 shares at a strike of $2.44 and sold $12,132,080 worth of shares (400,000 units at $30.33) (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- SECCaris Life Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
- ANALYSTUBS initiated coverage on Caris Life Sciences with a new price targetUBS initiated coverage of Caris Life Sciences with a rating of Neutral and set a new price target of $28.00
- PRCaris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris DetectNew partnership highlights the importance of finding cancer earlier through Caris Detect, a multi-cancer early detection blood test now available nationwideIRVING, Texas, Sept. 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading TechBio company, today announced the launch of its new national campaign titled, "Math," featuring the iconic, award-winning actor, producer and director, Kevin Costner. The partnership is designed to raise awareness of the critical importance of early cancer detection and introduce a national audience to Caris Detect™, Caris' groundbreaking multi-cancer early detection (MCED) blood test.
- PRCaris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung CancerSeven studies will be presented, including two mini oral presentations and a poster tour presentationIRVING, Texas, Sept. 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present seven studies at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), taking place September 12-15, 2026, in Seoul, South Korea. Caris research includes two mini oral presentations, one Poster Tour presentation and four poster presentations highlighting how comprehensive molecular profiling and AI-driven clinico-genomic
- PRCaris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic CancerCaris AI Insights for pancreatic cancer is proprietary, only available to Caris Life Sciences customers and not achievable through small panelsIRVING, Texas, Aug. 27, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading TechBio company, today announced the publication of a study in npj Precision Oncology describing the development and validation of an AI-driven approach to optimize first-line treatment selection in pancreatic cancer, advancing a more personalized care path for one of the deadliest malignancies. The study demonstrates the performance of Caris AI Insights™ to predict first-line treatment benefit usin
- SECSEC Form 144 filed by Caris Life Sciences Inc.144 - Caris Life Sciences, Inc. (0002019410) (Subject)
- INSIDERDirector Castleman Peter M was granted 13,192 shares, increasing direct ownership by 82% to 29,321 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Phillips T Danny was granted 13,192 shares, increasing direct ownership by 11% to 133,060 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Minor Lloyd was granted 13,192 shares, increasing direct ownership by 71% to 31,813 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Gilliam Joseph E was granted 13,192 shares, increasing direct ownership by 82% to 29,321 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Fredrickson David Paul was granted 13,192 shares, increasing direct ownership by 71% to 31,813 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Vacirca Jeff L was granted 13,192 shares, increasing direct ownership by 27% to 62,863 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Johansen Laura I was granted 13,192 shares, increasing direct ownership by 4% to 343,897 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- INSIDERDirector Halbert Jon was granted 13,192 shares, increasing direct ownership by 11% to 131,813 units (SEC Form 4)4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)
- SECSEC Form 144 filed by Caris Life Sciences Inc.144 - Caris Life Sciences, Inc. (0002019410) (Subject)
CAI FAQ
11 questionsWhat does Caris Life Sciences Inc. do?
CAI International, Inc. operates as a transportation finance company in the United States, Switzerland, France, Korea, Singapore, rest of Asia, rest of Europe, and internationally. The company leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. It leases its container equipment to lessees under long-term, short-term, and finance leases. The company also sells containers; and manages equipment for to third-party investors, as well as sells used containers. As of December 31, 2020, it had a container fleet comprised 1,798,520 cost...What is the latest news on CAI?
In the last 30 days Quantisnow tracked 7 wire items for CAI: 2 press releases and news items, 2 earnings updates, 2 SEC filings and 1 13D/G filing. The most recent was published on November 5, 2026.What is CAI revenue?
Caris Life Sciences Inc. (CAI) reported $1.05B of revenue for the twelve months ended Sep 30, 2026. That is up 61.5% from the year before. Revenue for fiscal 2025 was $812.03M.Is CAI profitable?
Yes. Caris Life Sciences Inc. earned $96.06M in net income for the twelve months ended Sep 30, 2026, a net margin of 9.2%.How much cash and debt does CAI have?
Caris Life Sciences Inc. reported $393.27M of debt on its most recent balance sheet in SEC filings.Where does CAI stock trade?
Caris Life Sciences Inc. (CAI) is listed on NASDAQ.What sector and industry is CAI in?
Caris Life Sciences Inc. operates in the Health Care sector, Medical Specialities industry.When did Caris Life Sciences Inc. go public?
Caris Life Sciences Inc. (CAI) completed its IPO in 2025.What are analysts saying about CAI?
Caris Life Sciences Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Neutral with a $28.00 price target on 2026-09-09. Recent price targets range from $21.00 to $31.00.What companies are similar to CAI?
Notable peers in the same industry include ELV (Elevance Health Inc.), HUM (Humana Inc.), NTRA (Natera Inc.), CI (The Cigna Group), UNH (UnitedHealth Group Incorporated). Compare CAI side-by-side with any of them on Quantisnow.How can I track CAI on Quantisnow?
Quantisnow aggregates Caris Life Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CAI to receive live email and push alerts on every new disclosure.